Cluvot 1250 j.m.

Package leaflet: Information for the patient

Cluvot 1250 i.u.
powder and solvent for solution for injection / infusion
Human blood coagulation factor XIII
Please read all of this leaflet carefully before using this medicine, because it contains
information important for the patient.

• Keep this leaflet, so that you can read it again if necessary.
• If you have any questions, please consult your doctor or pharmacist.
• This medicine has been prescribed for a specific individual. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same.
• If you experience any adverse reactions, including any adverse reactions not listed in this leaflet, inform your doctor or pharmacist. See section 4.

Table of contents of the leaflet

1. What Cluvot is and what it is used for
2. Important information before using Cluvot
3. How to use Cluvot
4. Possible side effects
5. How to store Cluvot
6. Contents of the pack and other information

1. What Cluvot is and what it is used for

What Cluvot is
Cluvot is a medicine available as a white powder and solvent. The reconstituted solution should be administered by intravenous injection.
Cluvot is human coagulation factor XIII (F XIII) derived from human plasma (the liquid component of blood) and plays an important role in the haemostatic process (stopping bleeding).

What Cluvot is used for
Cluvot is indicated for use in adults, children and adolescents:

• for prophylactic treatment of congenital factor XIII deficiency, and
• in perioperative management for the treatment of bleeding during surgical procedures in patients with congenital factor XIII deficiency.

2. Important information before using Cluvot

This section of the leaflet contains information to be considered before starting treatment with
Cluvot.
When not to use Cluvot:

• if the patient is allergic to the active substance or to any of the other ingredients of this medicine (listed in section 6). The doctor should be informed if there is hypersensitivity to any drug or food.

Warnings and precautions:

• if allergic reactions occurred in the past after administration of factor XIII blood clotting factor. Antihistamines and corticosteroids should be administered prophylactically if the doctor decides so.
• if symptoms of allergy or anaphylactic-type reactions occur (severe allergic symptoms may cause significant breathing difficulties or dizziness). Administration of Cluvot must be immediately stopped (i.e. interruption of injection or infusion). In case of shock, treatment should be initiated according to current medical standards.
• if recent thrombosis (blood clot) has occurred. The patient should be carefully monitored due to the fibrin-stabilizing effect of FXIII.
• development of inhibitors (neutralizing antibodies) is a known complication of treatment and means that the treatment stops being effective. If bleeding is not controlled with Cluvot, the doctor should be informed immediately. The patient should be closely monitored for the development (appearance) of inhibitors.

The doctor should always weigh the benefits of treatment against the risks associated with
complications.
Viral safety
When medicines are manufactured from human blood or plasma, various measures are taken to
protect patients from transmission of infectious agents. These methods include:

• appropriate selection of blood and plasma donors to exclude the risk of transmission of infectious agents
• testing of each donation and plasma pools for the presence of markers of viruses/infections
• inclusion in the manufacturing process of blood or plasma products of steps that can lead to inactivation or removal of viruses.

Despite the application of the above-mentioned methods, it cannot be completely excluded that
administration of a medicinal product derived from human blood or plasma may transmit infectious
agents. This risk also applies to unknown or newly emerging viruses and other infectious agents.
The protective measures taken are effective against enveloped viruses such as human immunodeficiency
virus (HIV, the virus causing AIDS), hepatitis B virus (HBV, causing hepatitis B), hepatitis C virus (HCV,
causing hepatitis C), as well as against non-enveloped viruses such as hepatitis A virus (HAV, causing
hepatitis A) and parvovirus B19.
In patients repeatedly receiving products derived from human plasma, vaccination against hepatitis A
and B should be considered.
It is recommended that whenever Cluvot is administered, the date of administration, batch number,
and volume infused should be recorded in the patient's documentation.
Cluvot and other medicines

• Inform the doctor or pharmacist about any other medicines being taken, including those available without a prescription.
• No interactions between the blood coagulation factor FXIII concentrate and other medicinal products are known.
• Cluvot must not be mixed with other medicinal products, solvents, or diluents, except those mentioned in section 6, and should be administered using separate infusion sets.

Pregnancy and breastfeeding

• If the patient is pregnant or breastfeeding, suspects she may be pregnant, or is planning to have a child, she should consult her doctor or pharmacist before using this medicine.
• Limited clinical data on the use of Cluvot during pregnancy have not shown any adverse effects on pregnancy or embryonic and postnatal development. If necessary, Cluvot may be considered for use during pregnancy.
• It is not known to what extent Cluvot passes into human milk; however, due to its high molecular weight, excretion in breast milk is very unlikely, and because of its protein nature, absorption of intact molecules by the newborn is also unlikely. Therefore, Cluvot may be used during breastfeeding.
• There are no data on the effect of Cluvot on fertility.

Driving and operating machinery
No studies have been conducted on the effect on the ability to drive vehicles and operate machinery.
Important information about some ingredients of Cluvot
Cluvot contains sodium.
It should be noted that Cluvot contains sodium. This is important for patients on a controlled low-sodium
diet. Cluvot contains 124.4 to 195.4 mg (5.41 to 8.50 mmol) of sodium per dose (40 IU/kg body weight – based on an average body weight of 70 kg), when the recommended dose (2800 IU = 44.8 ml) is administered.

3. How to use Cluvot

• Cluvot is usually administered by a healthcare professional.
• Cluvot is intended for intravenous use only.

Dosage
The appropriate dose and frequency of Cluvot administration should be determined by the physician, taking into account the patient's progress in treatment.
For more detailed recommendations, see section: "Information intended exclusively for medical personnel or healthcare professionals".

Overdose
Cases of overdose have not been reported and are not expected when this medicine is administered by healthcare professionals.

4. Possible adverse reactions

Like all medicines, this medicine can cause adverse reactions, although not everyone experiences them.
The following adverse reactions have been observed rarely (occurred in more than 1 in 10,000 patients
and less than 1 in 1,000):

• Allergic reactions such as generalized urticaria (itchy skin rash), hypotension (which may cause dizziness or feeling faint), difficulty in breathing.
• Increase in body temperature

The following adverse reactions have been observed very rarely (occurred in less than 1 in 10,000
patients):

• Formation of FXIII inhibitors.

If allergic reactions occur, administration of Cluvot should be immediately discontinued
and appropriate treatment initiated. Current medical standards for the treatment of shock should be applied.
Adverse reactions in children and adolescents
Adverse reactions in children are expected to be the same as in adults.
Reporting of adverse reactions
If any adverse effects occur, including any adverse effects not listed in this leaflet, inform your doctor or pharmacist. Adverse reactions can be reported directly to the Department of Monitoring Adverse Drug Reactions at the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Al. Jerozolimskie 181C,
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Adverse reactions can also be reported to the marketing authorization holder.
Reporting adverse reactions helps to provide more information on the safety of the medicine.

5. How to store Cluvot

• Store in a refrigerator (2 °C - 8 °C).
• Do not freeze.
• Keep in the outer packaging to protect from light.
• Cluvot does not contain preservatives. The medicinal product should be used immediately after reconstitution. If not used immediately, storage at room temperature should not exceed 4 hours. Do not store the reconstituted solution in the refrigerator and do not freeze it.
• Keep the medicine out of the sight and reach of children.
• Do not use Cluvot after the expiry date stated on the label and outer packaging following the abbreviation EXP.
• The product batch number is indicated on the outer packaging and label following the abbreviation: Lot.

6. Contents of the package and other information

What Cluvot contains
Active substance:
Human coagulation factor XIII (FXIII) concentrate containing 1250 IU per vial.
Other ingredients:
Human albumin, glucose monohydrate, sodium chloride, sodium hydroxide (in small amounts for pH adjustment).
Solvent: Water for injections

What Cluvot looks like and contents of the pack
Cluvot is supplied as a white powder and accompanying solvent, which is water for injections.
The reconstituted solution should be colourless, clear to slightly opalescent. When held up to the light, it should not be cloudy or contain residues (clumps/particles).

Pack sizes
One 1250 IU pack contains:
1 vial of powder
1 vial of 20 ml water for injections
1 20/20 transfer system with filter (Mix2Vial)
Administration set (inner packaging):
1 single-use 20 ml syringe
1 infusion set
2 alcohol swabs
1 non-sterile plaster

Marketing Authorisation Holder and Manufacturer
CSL Behring GmbH
Emil-von-Behring-Strasse 76
35041 Marburg
Germany

Information intended exclusively for medical professionals:

Dosage
1 ml corresponds approximately to 62.5 IU, and 100 IU is equivalent to approximately 1.6 ml.
Important:
The required amount to be administered and the frequency of administration should always be adjusted according to the clinical response in individual patients.
Dosage
Dosage should be individually adjusted depending on body weight, laboratory test results, and the patient's clinical condition.
Routine dosage regimen for prophylaxis
Initial dose

• 40 international units (IU) per kilogram of body weight.
• The infusion rate should not exceed 4 ml per minute.

Subsequent doses

• Dosing should be determined based on the current FXIII activity level; doses should be administered at 28-day (4-week) intervals to maintain a minimum FXIII activity level of approximately 5 to 20%.
• Recommended dosage adjustment of +/- 5 IU per kg body weight should be calculated considering the measured minimum FXIII activity level as shown in Table 1 and the patient's clinical condition.
• Dosage adjustments should be based on a specific, sensitive assay used to measure FXIII levels. Examples of dosage adjustments using the standard Berichrom activity assay are presented in the table below (Table 1).

Table 1: Dosage adjustment using the Berichrom activity assay

The activity expressed in units is determined using the Berichrom activity test, which refers to the current International Standard for Blood Coagulation Factor XIII Plasma. Therefore, one unit corresponds to one International Unit.

Preoperative prophylaxis.
After the last dose administered in routine prophylaxis, in the case of a planned surgical procedure:

• Between 21 and 28 days after the last dose – the patient should receive a full dose immediately before surgery, and the next prophylactic dose should be administered 28 days later.
• Between 8 and 21 days after the last dose – an additional dose (full or partial) may be administered before surgery. The dose should be based on the patient's FXIII activity level, clinical condition, and should be adjusted according to the half-life of the medicinal product Cluvot.
• Within 7 days of the last dose – additional administration may not be necessary.

Dosage adjustment may differ from the recommended dosage and should be individually tailored based on the FXIII activity level and the patient's clinical condition. All patients should be closely monitored during and after surgery.
Therefore, monitoring of the increase in FXIII activity level based on the Factor XIII assay is recommended. In the case of major surgical procedures and significant bleeding, the target should be achieving levels close to normal values (healthy individuals: 70%–140%).

Children and adolescents
Dosing and administration in children and adolescents are based on body weight and therefore generally do not differ from adult recommendations. Dosing and/or frequency of administration for each patient should always be adjusted based on clinical efficacy and FXIII activity levels.

Elderly patients
Dosing and administration in elderly patients (>65 years of age) have not been documented in clinical trials.

Administration method

General instructions
The solution should be clear or slightly opalescent. After filtration/withdrawal of the vial contents (see below), the reconstituted product should be visually inspected before administration; check for any particulate matter or discoloration.
Do not use cloudy solutions or those containing flakes or particles.
Reconstitution and withdrawal from the vial must be performed under aseptic conditions.

Reconstitution
Allow the diluent to reach room temperature. Remove the plastic caps from the vials containing the powder and diluent, and clean the stoppers with an aseptic solution. After drying, open the Mix2Vial connector system.

1	1. Open the packaging containing the Mix2Vial by removing the cap. Do not remove the Mix2Vial from the blister.
2	2. Place the vial with solvent on a flat, clean surface and hold it firmly. Without removing it from the blister, place the blue, blade-equipped end of the Mix2Vial system onto the stopper of the solvent vial and press vertically downward to pierce the stopper of the solvent vial.
3	3. Holding the edge of the Mix2Vial system, carefully remove the blister by pulling it vertically upward. Make sure to remove only the blister, not the entire Mix2Vial system.
4	4. Place the vial with powder on a flat, hard surface. Invert the solvent vial with the attached Mix2Vial system and insert the transparent end's piercing tip into the stopper of the powder vial by pressing vertically downward. The solvent will automatically transfer into the vial containing the powder.
5	5. With one hand, hold the part of the Mix2Vial system attached to the vial now containing the solution; with the other hand, hold the connector part attached to the solvent vial and carefully unscrew the two connector parts from each other. Remove the empty solvent vial with the attached blue end of the Mix2Vial system.
6	6. Gently swirl the vial attached to the transparent end of the Mix2Vial system, which contains the solution, until the medicinal product is completely dissolved. Do not shake.
7	7. Draw air into an empty, sterile syringe. Holding the vial with the medicinal product upright with the stopper facing upward, attach the syringe to the Luer Lock connector of the Mix2Vial system. Inject air into the vial with the medicinal product.

Administration and method of administration

8	8. Holding the syringe plunger, invert the vial with the syringe upside down and draw the solution into the syringe by slowly pulling back the plunger.
9	9. After filling the syringe with the solution, firmly grasp the syringe barrel (holding the syringe with the plunger facing downward) and disconnect the clear end of the Mix2Vial system from it.

Care should be taken to ensure that blood does not enter the syringe filled with the medicinal product, as there is a risk that blood may clot within the syringe and fibrin clots could be administered to the patient.
The reconstituted solution should be administered through separate injection/infusion sets (supplied with the product) by slow intravenous injection at a rate not exceeding 4 ml per minute.
Any unused medicinal products and waste materials should be disposed of in accordance with local requirements.